Search Medical Condition
Please enter condition
Please choose location

Chongju, Korea, Republic of Clinical Trials

A listing of Chongju, Korea, Republic of clinical trials actively recruiting patients volunteers.

RESULTS

Found (20) clinical trials

Efficacy and Safety of Lacosamide as Adjunctive Therapy in Subjects 1 Month to < 4 Years With Partial-onset Seizures

The trial consists of a 7-day Baseline Period, a 20-day Titration Period, a 7-day Maintenance Period, and a 12-day Transition Period for subjects who complete the study and choose to enter the extension study. Subjects who will not enter the extension study will continue after the Maintenance Period with a ...

Phase

0.0 miles

Learn More »

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

This is a Phase Ib, open-label, multicentre study of AZD9291 administered orally in combination with novel therapeutics (AZD6094 or selumetinib (AZD6244, ARRY142886)) to patients with EGFRm+ advanced NSCLC. The study has been designed to allow an investigation of the optimal combination dose and schedule whilst ensuring the safety of patients ...

Phase

0.0 miles

Learn More »

A Dose Escalation Study of JNJ-61186372 in Participants With Advanced Non-Small Cell Lung Cancer

This open label (all participants know the identity of the study drug), multicenter (more than one study site), first-in-human study consists of 2 parts. Part 1 is a dose escalation and Part 2 is a dose expansion cohort. In Part 1, participants with evaluable non-small cell lung cancer (NSCLC) will ...

Phase

0.0 miles

Learn More »

Safety and Optimal Neuroprotection of neu2000 in Ischemic Stroke With Endovascular reCanalizion (SONIC)

Neu2000 was designed as a multi-target neuroprotectant preventing both the NMDA receptor, a Ca2+-permeable glutamate receptor, and free radicals, two major routes of brain cell death in stroke. Neu2000 is a moderate NR2B-selective NMDA receptor antagonist and spin trapping molecule (=free radical scavenger or antioxidant). Therapeutic potential of Neu2000 has ...

Phase

0.0 miles

Learn More »

Effect and Efficacy of Xpedition /Alpine Everolimus-eluting Stent for Coronary Atherosclerosis

Secondary endpoints of this study are Stent thrombosis-24 hours(acute), 30 days(subacute), 1 year(late), every 1 year till 3 years(very-late) after index PCI Target vessl failure Composite rate of cardiac death and any MI, 3 years Composite rate of all death and any MI Composite rate of all death, any MI, ...

Phase N/A

0.0 miles

Learn More »

A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients

This study is designed as a phase III, prospective, randomized, open-label, multicenter clinical trial comparing GV1001 concurrent with Gemcitabine/Capecitabine versus Gemcitabine/Capecitabine alone in treating locally advanced and metastatic pancreatic cancer patients. Patients will be treated until disease progression and will be subject to follow-up until death. Patients will be randomized ...

Phase

0.0 miles

Learn More »

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Oversight Authorities continued: Colombia- pending regulatory approval

Phase

0.0 miles

Learn More »